Climb Bio, Inc. filed a Current Report on Form 8-K on November 5, 2026, announcing the release of its financial results for the quarter ended September 30, 2026, and an updated corporate presentation.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Press release: Climb Bio issued a press release on November 5, 2026, announcing the quarterly financial results, attached as Exhibit 99.1.
  • Corporate presentation: An updated investor presentation was published on November 5, 2026, furnished as Exhibit 99.2.
  • Emerging growth company: The filing identifies Climb Bio as an emerging growth company under applicable SEC rules.
  • Signatory: The report was signed by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer.

Climb Bio Discloses Q3 2026 Results and Updated Investor Presentation

Climb Bio, Inc. (NASDAQ:CLYM), headquartered in Wellesley Hills, Massachusetts, filed a Current Report with the SEC on November 5, 2026, under Item 2.02, Results of Operations and Financial Condition. According to the filing, the company issued a press release on that date announcing its financial results for the quarter ended September 30, 2026. That press release is attached to the report as Exhibit 99.1 and incorporated by reference.

The filing also includes a disclosure under Item 7.01, Regulation FD. According to the report, Climb Bio published an updated corporate presentation on November 5, 2026, furnished as Exhibit 99.2. The filing notes that the information provided under Items 2.02 and 7.01, including the attached exhibits, is being "furnished" rather than "filed" and therefore is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933.

The company is incorporated in Delaware and carries Commission File Number 001-40708. Its common stock, with a par value of $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol CLYM. The filing was signed by President and Chief Executive Officer Aoife Brennan, M.B., Ch.B., on November 5, 2026.

What Was Disclosed

Climb Bio filed an 8-K on November 5, 2026, announcing third-quarter 2026 financial results via a press release and furnishing an updated investor presentation, both dated November 5, 2026, as exhibits to the report.